SPRB
What one share of Spruce Biosciences holds
Pharmaceutical Preparations
We are a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need. We have a diverse portfolio of product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are either no approved therapies treating the underlying disease or suboptimal treatment options.
Spruce Biosciences’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$36.05 |
|---|---|
| Cash and investments | $34.98 |
| Debt | $6.03 |
| Book value | $30.42 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2019 | — | −$17.12 | $0.01 | −$16.51 | — | −$40.08 |
| 2020 | — | −$4.93 | $0.01 | −$4.61 | — | — |
| 2021 | — | −$1.81 | $0.00 | −$1.54 | — | $4.74 |
| 2022 | $0.00 | −$1.96 | $0.00 | −$1.77 | — | $2.90 |
| 2023 | $0.26 | −$1.24 | $0.00 | −$0.86 | — | $1.86 |
| 2024 | $8.93 | −$96.40 | $0.00 | −$101.73 | — | $51.19 |
| 2025 | $0.00 | −$50.83 | — | −$43.47 | — | $30.99 |